While laboratory findings have been intriguing, human clinical evidence remains extremely limited , making it important to separate scientific possibility from proven treatment
FDA on the 503A bulk substances Category 2 list in 2023 , removing it from compounding pharmacy eligibility on the grounds that human safety, immunogenicity, and PK data were insufficient
It is small, stable and extraordinarily bioactive: published research links GHK-Cu to modulation of more than 4,000 genes affecting collagen , elastin , antioxidant defence , angiogenesis and wound repair
Vitamin B 12 replacement therapy was effective
BPC-157 Arginate + PEA BPC-157 Arginate preclinical compound profile
Copper peptides continue to be a growing topic of interest in personalized skin care conversations